Oral ximelagatran for secondary prophylaxis after myocardial infarction: The ESTEEM randomised controlled trial

Lancet

Volumn 362, Issue 9386, 2003, Pages 789-797

  Wallentin, Lars ^a   Wilcox, Robert G ^b   Weaver, W Douglas ^c   Emanuelsson, Håkan ^d   Goodvin, Andrew ^d   Nyström, Per ^e   Bylock, Anders ^e  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^c HENRY FORD HOSPITAL   (United States)

^d ASTRAZENECA   (United Kingdom)

^e ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; THROMBIN INHIBITOR; XIMELAGATRAN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLEEDING; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EPISTAXIS; FEMALE; GINGIVA BLEEDING; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMATOMA; HEMATURIA; HUMAN; JAUNDICE; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; PROPHYLAXIS; PURPURA; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SIDE EFFECT; ST SEGMENT ELEVATION;

EID: 0041829444     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)14287-0     Document Type: Article

References (30)

1. Cairns J.A., Théroux P., Lewis H.D. Jr, Ezekowitz M., Meade T.W. Antithrombotic agents in coronary artery disease. Chest. 119:2001;S228-S252.
2. Bertrand M.E., Simoons M.L., Fox K.A.A., et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 23:2002;1809-1840.
3. Braunwald E., Antman E.M., Beasley J.W., et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation. 106:2002;1893-1900.
4. Van de Werf F., Ardissino D., Betriu A., et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The task force on the management of acute myocardial infarction of the European Society of Cardiology. Eur Heart J. 24:2003;28-66.
5. Theroux P., Waters D., Lam J., Juneau M., McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med. 327:1992;141-145.
6. Low-molecular-weight heparin during instability in coronary artery disease. Lancet. 347:1996;561-568.
7. A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, for unstable coronary artery disease in 1209 patients. Eur Heart J. 18:1997;1416-1425.
8. Wallentin L., Bergstrand L., Dellborg M., et al. Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study. Eur Heart J. 24:2003;897-908.
9. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 324:2002;71-86.
10. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 345:2001;494-502.
11. Hurlen M., Abdelnoor M., Smith P., Erikssen J., Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 347:2002;969-974.
12. Van Es R.F., Jonker J.J., Verheugt F.W., Deckers J.W., Grobbee D.E. Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis-2 (ASPECT-2) Research Group. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet. 360:2002;109-113.
13. Eriksson U.G., Bredberg U., Hoffmann K.-J., et al. Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. Drug Metab Dispos. 31:2003;294-305.
14. Johansson L.C., Frison L., Lofgren U., Fager G., Gustafsson D., Eriksson U.G. Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin Pharmacokinet. 42:2003;381-392.
15. Sarich T.C., Peters G.R., Wollbratt M., Homolka R., Svensson M., Eriksson U.G. No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor, ximelagatran. Clin Pharmacokinet. 42:2003;485-492.
16. Johansson L.C., Andersson M., Fager G., Gustafsson D., Eriksson U.G. No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran, following oral administration of ximelagatran, a novel, oral direct thrombin inhibitor, to healthy male volunteers. Clin Pharmacokinet. 42:2003;475-484.
17. Eriksson-Lepkowska M., Thuresson A., Johansson S., et al. The oral direct thrombin inhibitor ximelagatran has no effect on the pharmacokinetics of P450-metabolized drugs. Pathophysiol Haemost Thromb. 32:2002;130.
18. Eriksson U.G., Bredberg U., Gislén K., et al. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young, healthy male subjects. Eur J Clin Pharmacol. 59:2003;35-43.
19. Fager G., Eriksson-Lepkowska M., Frison L., Bylock A., Ahnoff M., Eriksson U.G. Influence of acetylsalicylic acid on the pharmacodynamics and pharmacokinetics of melagatran, the active form of the oral direct thrombin inhibitor H 376/95. Eur Heart J. 21:(Suppl):2000;441.
20. Sarich T.C., Eriksson U.G., Mattsson C., et al. Inhibition of thrombin generation by the oral direct thrombin inhibitor ximelagatran in shed blood from healthy male subjects. Thromb Haemost. 87:2002;300-305.
21. Eriksson B.I., Bergqvist D., Kälebo P., et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet. 360:2002;2441-2447.
22. Petersen P., Grind M., Adler J. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: A dose-guiding, tolerability and safety study. J Am Coll Cardiol. 41:2003;1445-1451.
23. Eriksson H., Wåhlander K., Gustafsson D., Welin L.T., Frison L., Schulman S. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemost. 1:2003;41-47.
24. Myocardial infarction redefined - A consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial infarction. Eur Heart J. 21:2000;1502-1513.
25. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet. 354:1999;701-707.
26. Antman E.M., McCabe C.H., Gurfinkel E.P., et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation. 100:1999;1593-1601.
27. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. Lancet. 359:2002;294-302.
28. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomized trial in acute myocardial infarction. Lancet. 358:2002;605-613.
29. Eriksson H., Wåhlander K., Lundström T., Billing Clason S., Schulman S. Extended secondary prevention with the oral direct thrombin inhibitor ximelagatran for 18 months after 6 months of anticoagulation in patients with venous thromboembolism: a randomized, placebo-controlled trial. Blood. 100:2002;81a.
30. Ohlsson BS, on behalf of the SPORTIF III Investigators. Stroke prevention using the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation: the SPORTIF III trial. Lancet (in press).